Table 2

Description of the resolved PDRP with the pharmaceutical care programme

Categories of PDRP*N (%)
Health problem insufficiently treated39 (47.6)
Inappropriate dose, dosage schedule and/or duration24 (29.3)
Interactions6 (7.3)
Duplicity3 (3.7)
Wrongly administered drug1 (1.2)
Other9 (11.0)
ATC Group of the active ingredient involved in the resolved PDRP
A (Alimentary tract and metabolism)10 (12.2)
B (Blood and blood-forming organs)7 (8.5)
C (Cardiovascular system)27 (32.9)
C/G (Cardiovascular system)/(Genitourinary system and sex hormones)1 (1.2)
G (Genitourinary system and sex hormones)3 (3.7)
J (Anti-infective agents for systemic use)5 (6.1)
B/J (Blood and blood-forming organs)/(Anti-infective agents for systemic use)4 (4.9)
L (Antineoplastic and immunomodulating agents)3 (3.7)
M (Musculoskeletal system)3 (3.7)
N (Nervous system)6 (7.3)
R (Respiratory system)6 (7.3)
S (Sensory organs)4 (4.9)
V (Various)3 (3.7)
Procedures followed to detect PDRP
Elaboration and record DTC/medication reconciliation (admission)37 (45.1)
Medication reconciliation (discharge)/supplying information (discharge)17 (20.7)
Physician prescription validation/patient follow-up28 (34.1)
  • *PDRP according to the Third Consensus of Granada 17 classification (n=82).

  • DTC, drug treatment chart; PDRP, potential drug-related problem.